TOKYO -- Japanese drugmaker Shionogi announced a partnership with a Chinese counterpart on Thursday to promote its oral COVID-19 treatment in China, as the country grapples with a surging outbreak.
The licensing agreement with Chia Tai Tianqing Pharmaceutical Group will let the Chinese company market the drug, known as Xocova, to medical institutions and pharmacies if it is approved by Chinese authorities.
